Meanwhile, HSP60 was evidenced to exert a regulatory function in patients with cisplatin-resistant ovarian cancer [75], in which high expression of HSP60 can decrease the survival rate after cisplatin chemotherapy. Here, HSPD1 is linked to ovarian carcinoma.